CASI Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing innovative therapeutics and pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 233 full-time employees. The company went IPO on 2021-08-23. The firm is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The firm is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Company’s Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.
Follow-Up Questions
CASI Pharmaceuticals Inc のCEOは誰ですか？
Dr. Wei-Wu He は CASI Pharmaceuticals Inc の Chairman of the Board で、2012 から在籍しています。
CASI の株価パフォーマンスは？
CASI の現在の価格は $1.68 で、最終取引日から 2.77% increased 変動しました。
CASI Pharmaceuticals Inc の主な事業テーマや業界は？
CASI Pharmaceuticals Inc は Biotechnology 業界、セクターは Health Care に属しています。
